Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the efficacy and safety of pemigatinib in participants with relapsed or refractory advanced non-small cell lung cancer with FGFR alter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2024-08-06